VJHemOnc is committed to improving our service to you

ASH 2017 | ABVD vs. escBEACOPP in HL: a 10-year study

VJHemOnc is committed to improving our service to you

George Follows

In the UK, escalated BEACOPP (escBEACOPP) was introduced as an alternative to ABVD for the treatment of advanced-stage Hodgkin lymphoma (HL). Here, George Follows, BMBCh, PhD, FRCP, FRCPath, of Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses the 10-year retrospective study of ABVD vs. escBEACOPP in HL patients in both trial (RATHL; Trial: RATHL, NCT00678327) and non-trial settings. Dr Follows expresses excitement at presenting the data at this year’s American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter